From the observation DAC: romidepsin revisited.

摘要

he number of noncy to toxic drugs featuring significant single-agent activity in relapsed or relapsed and refractory (disease progression during treatment or within 60 days of its termination) myeloma is clearly limited. The proteasome inhibitors and the imuno-modulatory derivatives of thalidomide (IMiDs) have proven effective, with several compounds already in routine clinical care. As duration of response to either drug or drug combination is restricted, further options are needed.